<DOC>
	<DOCNO>NCT00778882</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy administration autologous hematopoietic stem cell transduce MT-gp91 retroviral vector patient X-linked chronic granulomatous disease .</brief_summary>
	<brief_title>Gene Therapy Chronic Granulomatous Disease Korea</brief_title>
	<detailed_description />
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>gp91 defective male patient chronic granulomatous disease : confirm DHR Weigh great equal 15 kg History severe infection : 2 time Performance status : ECOG 02 Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . Heart : shortening fraction &gt; 28 % ; QTc interval &lt; 0.44 Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal ; AST &lt; 3 x upper limit normal Kidney : creatine &lt; 2 x normal Blood : WBC &gt; 2,500/uL ; platelet &gt; 100,000/uL ; hematocrit &gt; 26 % Written inform consent obtain patient ( guardian patient age &lt; 19 ) Presence HLAmatched sibling stem cell donation Evidence history malignant tumor Presence severe infection Presence active tuberculosis Uncorrectable electrolyte , Ca , P Unable comply protocol cooperate fully Investigator site personnel</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Granulomatous Disease</keyword>
	<keyword>Retroviral Vector</keyword>
	<keyword>Gene Therapy</keyword>
</DOC>